Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Früh

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Swiss Medical Weekly|June 27, 2013
Tobacco-related cancer mortality: projections for different geographical regions in SwitzerlandVerena Jürgens, Silvia Ess, Harish C Phuleria, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2019
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLCAnne Schett, Sacha I Rothschild, Alessandra Curioni-Fontecedro, et al.
The European Respiratory Journal|August 26, 2017
Treatment of limited disease small cell lung cancer: the multidisciplinary teamMarkus Glatzer, Achim Rittmeyer, Joachim Müller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, et al.
The Oncologist|June 9, 2017
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell CancerMarco Siano, Francesca Molinari, Vittoria Martin, et al.
Cancer Immunology, Immunotherapy : CII|September 2, 2018
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)Sabine Schmid, Stefan Diem, Qiyu Li, et al.
Oncoimmunology|December 22, 2016
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancerOmar Hasan Ali, Stefan Diem, Eva Markert, et al.
Oncoimmunology|December 16, 2021
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancerMaximilian Boesch, Florent Baty, Werner C Albrich, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitorsOmar Hasan Ali, Fiamma Berner, David Bomze, et al.
Basic & Clinical Pharmacology & Toxicology|April 27, 2017
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib TreatmentZinnia P Parra-Guillen, Peter B Berger, Manuel Haschke, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Swiss Medical Weekly|June 27, 2013
Tobacco-related cancer mortality: projections for different geographical regions in SwitzerlandVerena Jürgens, Silvia Ess, Harish C Phuleria, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2019
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLCAnne Schett, Sacha I Rothschild, Alessandra Curioni-Fontecedro, et al.
The European Respiratory Journal|August 26, 2017
Treatment of limited disease small cell lung cancer: the multidisciplinary teamMarkus Glatzer, Achim Rittmeyer, Joachim Müller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, et al.
The Oncologist|June 9, 2017
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell CancerMarco Siano, Francesca Molinari, Vittoria Martin, et al.
Cancer Immunology, Immunotherapy : CII|September 2, 2018
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)Sabine Schmid, Stefan Diem, Qiyu Li, et al.
Oncoimmunology|December 22, 2016
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancerOmar Hasan Ali, Stefan Diem, Eva Markert, et al.
Oncoimmunology|December 16, 2021
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancerMaximilian Boesch, Florent Baty, Werner C Albrich, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitorsOmar Hasan Ali, Fiamma Berner, David Bomze, et al.
Basic & Clinical Pharmacology & Toxicology|April 27, 2017
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib TreatmentZinnia P Parra-Guillen, Peter B Berger, Manuel Haschke, et al.
Pageof 10